Uma Thanarajasingram, M.D., Ph.D.
Assistant Professor of Medicine
Former Chief Medical Resident, Internal Medicine
Rotation Director, Internal Medicine Rheumatology Rotation

Lisa A. Kottschade, APRN, C.N.P.
Associate Professor of Oncology
Board Member, Alliance for Clinical Trials in Oncology
Member, Advance Practitioner Society for Hematology and Oncology

Locations:

• Geffen Auditorium (Live)
• Broadcast to SMH Alfred M-459 and MA 17-64
• Mayo Clinic Health System in Waycross (Video Conference)

Lunch available outside Geffen Auditorium and SMH Alfred M-459 on a first come, first serve basis

Learning Objectives:

• Describe the rationale for the use of immune check-point inhibitors (ICIs) in cancer therapy
• Recognize the spectrum of autoimmune toxicities, the so-called "immune-related adverse events" (irAEs) that occur as a consequence of ICI therapy
• Describe the challenges and unknowns in management of various irAEs

Financial Disclosure:

• Consultant - AstraZeneca, Annenberg Center for Health Sciences, BioPharma
• Grant/Research Support - Bristol Myers Squibb

Off Label/Investigational Uses:

• Various - treatment of immune-related adverse events

Accreditation Statement

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Credit Statement(s)

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.